Critical agreement aims to accelerate access to important antibiotics

Webinar – Antibiotic shortages: causes, consequences, and solutions

The first novel antibiotic treatment in GARDP’s clinical development portfolio on track for potential FDA approval

Protecting the #PowerOfAntibiotics

The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant infections. Together with private, public and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.

Antibiotic resistance can affect anyone, anywhere

Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. Millions of people suffer due to antibiotic resistance every year, and nearly 1.3 million people die. 


Raising our voices to protect the #PowerOfAntibiotics

A global crisis of antibiotic resistance

global crisis photo 1

Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.

Crowd of people walking street wearing masks

Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.

Close Up Of Grandmother Holding Hands With Baby Granddaughter Playing Game Together

Low- and middle-income countries, and certain population groups like children and the elderly, are hit hardest.

Asian girl sleeping In hospital bed

If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.

GARDP is acting now to counter drug resistance and save lives

Developing 5 new treatments
by 2025

GARDP’s “5 by 25” initiative aims to deliver five new treatments by 2025 for bacterial infections that pose the greatest threat to human health.

Access to antibiotics for patients in need around the world

GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.

Partnerships to revitalize antibiotic development

GARDP works with governments, the pharmaceutical and biotech industry, academia, and members from civil society around the world.